Scholars@Duke
Matthew Kyle Labriola

Matthew Kyle Labriola

Assistant Professor of Medicine
Medicine, Medical Oncology
20 Duke Medicine Circle, Box 103861, Durham, NC 27710
20 Duke Medicine Circle, Box 103861, Durham, NC 27710

Scholarly Works - Conferences

Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2026 5052Background: Smoking has been associated with increased metastatic prostate cancer ... Full text Cite

Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · March 1, 2026 228Background: Survival outcomes with sip-T in mCRPC are variable, and mechanisms dri ... Full text Cite

Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.

Conference Journal of Clinical Oncology · June 2025 e17107Background: In clinical practicea subset of patients treated with androgen deprivation therapy (ADT) plus an ARPI achie ... Full text Cite

Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).

Conference Journal of Clinical Oncology · June 2025 e17064Background: Analyses of clinical trials data suggest thatBlack men have equal or even improved overall survival (OS) wi ... Full text Cite

EMETPRO: A multicenter, international, retrospective analysis evaluating patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) with early progression (EP).

Conference Journal of Clinical Oncology · February 10, 2025 169Background: Combination therapies, such as androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) ... Full text Cite

Implementation outcomes of a multidisciplinary approach for Lu177-PSMA-617 therapy

Conference Journal of Clinical Oncology · January 1, 2024 Background: Lu177-PSMA-617 (LuPSMA) is a recently approved treatment for patients with metastatic castration resistant prostate cancer (mCRPC). Successful treatment in real-world practice requires coordination between nuclear medicine, radiation safety, an ... Full text Cite

Real-world clinical outcomes of patients treated with Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC): A single-institution experience

Conference Journal of Clinical Oncology · January 1, 2024 Background: The radiopharmaceutical Lu177-PSMA-617 (LuPSMA) was FDA approved in March 2022 for patients with mCRPC previously treated with both an androgen receptor signaling inhibitor (ARSI) and a taxane, if eligible based on PSMA PET. However, data regar ... Full text Cite

Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).

Conference Journal of Clinical Oncology · February 20, 2022 138 Background: AR alterations such as ligand binding domain mutations and amplification evolve under the selective pressure of testosterone suppression and AR targeted agents (ARTA) such as abiraterone or enzalutamide, but their ... Full text Cite

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Conference Journal of Clinical Oncology · February 20, 2022 129 Background: Pathogenic HRR gene mutations may confer sensitivity to PARP inhibitors (PARPi) and/or platinum chemotherapy (chemo). While pts harboring mutations in BRCA1/2 appear to benefit from these DNA damaging therapeutics ... Full text Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 e16079 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial, demonstrating little predictive utility in mRCC. TMB is pr ... Full text Cite

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Conference Journal of Clinical Oncology · May 20, 2019 e14291 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B) is a putative tumor suppressor gene spanning > 500 kb on chromosome 2. A melanoma study previously reported enrichment of LRP1B mutations in respon ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 2595 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · May 20, 2019 e14259 Background: Immune checkpoint inhibitors (ICIs) are standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. PD-L1 positivit ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 61 Background: Cell proliferation is an important marker of survival in many tumors and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors in RCC. Previously we reported (SITC 2018) m ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 62 Background: Cell proliferation is an important marker of survival in many tumors, and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors (ICIs) in RCC. Previously we reported (SITC ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 10, 2019 63 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial demonstrating little predictive utility in mRCC. TMB is predic ... Full text Cite

Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 400 Background: ICIs have expanded therapeutic options for mUC patients (pts); however, biomarkers such as PD-L1 have not served as reliable predictors of treatment efficacy. High tumor mutation burden (TMB) has been previously d ... Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 577 Background: Immune checkpoint inhibitors (ICIs) are now standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. Four different ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 607 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Engineered bone-inspired multicomponent bionanocomposite scaffolds with tunable hardness and modulus

Conference Materials Research Society Symposium Proceedings · December 1, 2012 We show a novel, bioengineered, moldable platform for bone regeneration composed of porous bionanocomposite scaffolds made of components that are normally found in bone tissue (calcium, collagen, carbonate, sodium, and phosphorous). To accommodate high- or ... Full text Cite